Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
NCT00310375
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
181
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
Ezogabine: USAN Retigabine (International Nonproprietary Name)
Sponsor
GlaxoSmithKline